Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoTherix Ventavis Clears FDA For Pulmonary Arterial Hypertension

This article was originally published in The Pink Sheet Daily

Executive Summary

Launch is planned for the second quarter following export clearance from regulators in Spain, where iloprost is manufactured. The timing will also allow CoTherix to hire and train the Ventavis sales force prior to making product available.

You may also be interested in...



CoTherix’ Ventavis Cleared For Combination Use

Ventavis’ expanded label addresses use of the inhaled pulmonary arterial hypertension therapy in combination with Actelion’s oral Tracleer.

CoTherix’ Ventavis Cleared For Combination Use

Ventavis’ expanded label addresses use of the inhaled pulmonary arterial hypertension therapy in combination with Actelion’s oral Tracleer.

Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says

The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.

Related Content

Topics

UsernamePublicRestriction

Register

PS058505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel